

Anavex Life Sciences (AVXL) was up 9.3% after the company said it is looking to accelerate clinical studies of treatments for Alzheimer's and Parkinson's disease by teaming up with Ariana Pharma and using its KEM patient stratification technology. The biopharmaceutical company said Wednesday it is hoping to use the KEM technology to speed up its phase 2/3 of the ANAVEX 2-73 study for Alzheimer's clinical development. KEM is a system that allows users to analyze datasets at rapid speeds, while identifying certain trends within the data.



Wall Street has **3,500** analysts, be sure you're taking the right advice.

[GET TIPRANKS >](#)

[HOME](#) [ANALYST INSIGHTS](#) [CONTRIBUTOR OPINIONS](#) [STOCK NEWS](#) [SECTORS](#) [PREMIUM SERVICES](#)

## Anavex Life Sciences Corp. (AVXL) Could See Accelerated Clinical Timelines in Alzheimer's Disease: Maxim

Julie Lamb, Editor - October 7, 2016, 12:55 PM EDT

SHARE ON: [f](#) [t](#) [p](#) [v](#) [e](#)

FIND MORE

### RELATED ARTICLES



FBR Reiterates Outperform on Anavex Life Sciences Corp. (AVXL) Following Agreement with Biogen

Jason Cohen, Editor, September 29,

2016

FBR Weighs in on Anavex Life

... . In addition, what we've been learning from CNS-based studies, whether AD or MS, is that the data are complex across multiple endpoints. As such, having the KEM system with Ariana in place to help analyze complex data is, in our view, a strategic positive for Anavex," Kolbert concludes.